中 文 摘 要
目的：通过系统的观察艾克达康颗粒治疗中期原发性肝癌CD4+、CD8+活性的影响，旨在对中医药治疗原发性肝癌机制进一步的探讨，为中西医结合治疗中期原发性肝癌提供一定的理论依据和可靠的研究资料。
方法：根据纳入病例标准将60例中期原发性肝癌患者随机分为治疗组30例和对照组30例。两组均给予常规对症支持及保肝治疗，治疗组在此基础上服用艾克达康颗粒，疗程为2个月。分别观察两组治疗前后中医症状改善情况CD4+、CD8+及CD4+/CD8+比值、肝功、甲胎蛋白等的变化，并与对照组进行对比，分析其差异。
结果：
1．治疗组（艾克达康颗粒组）在提高CD4+浓度及CD4+/CD8+比值方面均优于对照组，两者相比有显著性差异（P＜0.05）
2．治疗组在改善肝功、降低甲胎蛋白等方面效果优于对照组。
结论：
1．通过系统的临床观察，治疗组在提高CD4+T淋巴细胞浓度及CD4+/CD8+比值方面效果优于对照组，说明艾克达康颗粒可增强中期原发性肝癌患者机体免疫力。
2．艾克达康颗粒在中期原发性肝癌治疗中能够改善患者症状、改善肝功、提高生活质量，有确切疗效。
关键词：中期原发性肝癌
中医药治疗
改善机体免疫力
CD4+、CD8+
Objective: to observe the system through the middle reaches the kang Ike treatment of primary liver cancer CD4 +, CD8 + activity, the influence of traditional Chinese medicine to further discuss mechanism of primary liver cancer, combine traditional Chinese and western medicine treatment of primary liver cancer mid provide certain theoretical basis and reliable research material.
Methods: according to the standard will be 60 cases into the middle of primary liver cancer patients were randomly divided into treatment group and control group, 30 cases of 30 patients. Both groups to support and protect liver conventional treatment, the treatment group based on the use of kang particles, excel treatment for 2 months. Both groups were observed before and after the treatment of TCM symptoms improved conditions CD4 +, CD8 + and CD4 + / CD8 + ratio, liver, the change of fetal protein, and compared with control group, the analysis of the differences.
Results:
1 the treatment group (Ike reaches the kang group) in improving the particle concentration and CD4 + CD4 + / CD8 + ratio than in control group, compared with significant difference (P < 0.05),
2 in treatment group and reduces armour liver improving effect of fetal protein, etc.
Conclusion:
1 through clinical observation of the system, the treatment group in improving CD4 + T lymphocyte concentration and CD4 + / CD8 + ratio than control group, the effects of kang granules can enhance akpan mid-term primary liver cancer patients immunity.
2 in the middle of a particle akpan reaches the kang primary liver cancer treatment can improve the patient's symptoms, improve liver and improving the quality of life, have definite effect.
Keywords: metaphase of primary liver cancer
Traditional Chinese medicine
Improve immunity
CD4+、CD8+
Methods: according to the standard will be 60 cases into the middle of primary liver cancer patients were randomly divided into treatment group and control group, 30 cases of 30 patients. Both groups to support and protect liver conventional treatment, the treatment group based on the use of kang particles, excel treatment for 2 months. Both groups were observed before and after the treatment of TCM symptoms improved conditions CD4 +, CD8 + and CD4 + / CD8 + ratio, liver, the change of fetal protein, and compared with control group, the analysis of the differences.
Results:
1 the treatment group (Ike reaches the kang group) in improving the particle concentration and CD4 + CD4 + / CD8 + ratio than in control group, compared with significant difference (P < 0.05),
2 in treatment group and reduces armour liver improving effect of fetal protein, etc.
Conclusion:
1 through clinical observation of the system, the treatment group in improving CD4 + T lymphocyte concentration and CD4 + / CD8 + ratio than control group, the effects of kang granules can enhance akpan mid-term primary liver cancer patients immunity.
2 in the middle of a particle akpan reaches the kang primary liver cancer treatment can improve the patient's symptoms, improve liver and improving the quality of life, have definite effect.
Keywords: metaphase of primary liver cancer
Traditional Chinese medicine
Improve immunity
CD4+、CD8+
温馨提示：答案为网友推荐，仅供参考
第1个回答 2010-05-03
Objective: View 察艾克达康 particle therapy system, the medium-term primary liver CD4 +, CD8 + activity to the treatment of primary liver cancer in Chinese medicine to further explore the mechanism for Integrative Medicine essential medium HCC provides a theoretical basis and reliable research data.
Methods: 60 patients included in the standard case of the medium-term treatment of primary liver cancer were randomly divided into 30 cases and the control group 30. Both groups were given conventional treatment of symptomatic support and nourish the liver, the treatment group was based on taking Yikedakang particles, with a course of 2 months. Were clinical symptoms were observed before and after treatment to improve the situation of CD4 +, CD8 + and CD4 + / CD8 + ratio, liver function, AFP, etc. changes, compared with the control group to analyze the differences.
Results:
1. Treatment group (Yikedakang particle group) in increasing the concentration of CD4 + and CD4 + / CD8 + ratio were better than the control group, two significant differences compared (P <0.05)
2. Treatment group in improving liver function, and so reduce the effect of AFP than the control group.
Conclusion:
1. Through the system of clinical observation, the treatment group increased the concentration of CD4 + T lymphocytes and CD4 + / CD8 + ratio in respect better than the control group, said 明艾克达康 particles can enhance the medium-term immunity in patients with primary liver cancer.
2. Yikedakang particles in the mid-term treatment of primary liver cancer can improve symptoms, improve liver function and quality of life, have the exact effect.
Key words: medium-term primary liver cancer
TCM
Improve immunity
CD4 +, CD8 +
——————————————————————————————————————
绝对是正确的~~~~~~哦
Methods: 60 patients included in the standard case of the medium-term treatment of primary liver cancer were randomly divided into 30 cases and the control group 30. Both groups were given conventional treatment of symptomatic support and nourish the liver, the treatment group was based on taking Yikedakang particles, with a course of 2 months. Were clinical symptoms were observed before and after treatment to improve the situation of CD4 +, CD8 + and CD4 + / CD8 + ratio, liver function, AFP, etc. changes, compared with the control group to analyze the differences.
Results:
1. Treatment group (Yikedakang particle group) in increasing the concentration of CD4 + and CD4 + / CD8 + ratio were better than the control group, two significant differences compared (P <0.05)
2. Treatment group in improving liver function, and so reduce the effect of AFP than the control group.
Conclusion:
1. Through the system of clinical observation, the treatment group increased the concentration of CD4 + T lymphocytes and CD4 + / CD8 + ratio in respect better than the control group, said 明艾克达康 particles can enhance the medium-term immunity in patients with primary liver cancer.
2. Yikedakang particles in the mid-term treatment of primary liver cancer can improve symptoms, improve liver function and quality of life, have the exact effect.
Key words: medium-term primary liver cancer
TCM
Improve immunity
CD4 +, CD8 +
——————————————————————————————————————
绝对是正确的~~~~~~哦
